MaxCyte proposes dual listing on Nasdaq
Cell engineering technology company MaxCyte has submitted a draft registration statement with the Securities and Exchange Commission (SEC), it announced on Friday, for a proposed dual-listing and public offering of shares on the Nasdaq market.
The AIM-traded firm said the number of securities to be offered and the price for the proposed offering had not yet been determined.
“The offering is expected to commence after the SEC completes its review process, subject to market and other conditions, and shareholders and potential investors should note that the proposed offering may or may not proceed,” the board said in its statement.
At 0841 BST, shares in MaxCyte were down 0.44% at 896p.